Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of nearly 500 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.
SCRI, an industry leader in clinical trials, is dedicated to advancing therapies for patients through clinical research. SCRI conducts the largest community-based research program in the nation, including clinical trials in ten therapeutic areas through its affiliation with a powerful network of hundreds of physicians. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.
- Our work-SCRI is a research institution that sponsors oncology clinical trials through its affiliation with clinical oncology practices throughout the country. This work makes it possible for thousands of patients to participate in research studies close to home.
- Our services to physician investigators and industry—SCRI provides research support services to physicians and drug development sponsors across the country.